Autoantibodies Against Angiotensin-converting Enzyme 2 and Immune Molecules Are Associated with COVID-19 Disease Severity

Overview

Journal Res Sq

Date 2023 Oct 16

PMID 37841848

Authors

Todd Bradley

Eric Geanes

Rebecca McLennan

Cas LeMaster

Affiliations

Soon will be listed here.

Abstract

Increased inflammation caused by SARS-CoV-2 infection can lead to severe coronavirus disease 2019 (COVID-19) and long-term disease manifestations referred to as post-acute sequalae of COVID (PASC). The mechanisms of this variable long-term immune activation are poorly defined. Autoantibodies targeting immune factors such as cytokines, as well as the viral host cell receptor, angiotensin-converting enzyme 2 (ACE2), have been observed after SARS-CoV-2 infection. Autoantibodies to immune factors and ACE2 could interfere with normal immune regulation and lead to increased inflammation, severe COVID-19, and long-term complications. Here, we deeply pro led the features of ACE2, cytokine, and chemokine autoantibodies in samples from patients recovering from severe COVID-19. We identified epitopes in the catalytic domain of ACE2 targeted by these antibodies, that could inhibit ACE2 function. Levels of autoantibodies targeting ACE2 and other immune factors could serve as determinants of COVID-19 disease severity, and represent a natural immunoregulatory mechanism in response to viral infection.

References

Casanova J, Su H . A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection. Cell. 2020; 181(6):1194-1199. PMC: 7218368. DOI: 10.1016/j.cell.2020.05.016. View

Jawad B, Adhikari P, Podgornik R, Ching W . Key Interacting Residues between RBD of SARS-CoV-2 and ACE2 Receptor: Combination of Molecular Dynamics Simulation and Density Functional Calculation. J Chem Inf Model. 2021; 61(9):4425-4441. DOI: 10.1021/acs.jcim.1c00560. View

Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y . The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021; 20(4):102792. PMC: 7892316. DOI: 10.1016/j.autrev.2021.102792. View

Patel S, Juno J, Lee W, Wragg K, Hogarth P, Kent S . Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences. Eur Respir J. 2021; 57(5). PMC: 7830336. DOI: 10.1183/13993003.03730-2020. View

Manry J, Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q . The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc Natl Acad Sci U S A. 2022; 119(21):e2200413119. PMC: 9173764. DOI: 10.1073/pnas.2200413119. View

Schultheiss C, Willscher E, Paschold L, Gottschick C, Klee B, Henkes S . The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med. 2022; 3(6):100663. PMC: 9214726. DOI: 10.1016/j.xcrm.2022.100663. View

Knight J, Caricchio R, Casanova J, Combes A, Diamond B, Fox S . The intersection of COVID-19 and autoimmunity. J Clin Invest. 2021; 131(24. PMC: 8670833. DOI: 10.1172/JCI154886. View

Zuo Y, Estes S, Ali R, Gandhi A, Yalavarthi S, Shi H . Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020; 12(570). PMC: 7724273. DOI: 10.1126/scitranslmed.abd3876. View

Hallmann E, Sikora D, Poniedzialek B, Szymanski K, Kondratiuk K, Zurawski J . IgG autoantibodies against ACE2 in SARS-CoV-2 infected patients. J Med Virol. 2022; 95(1):e28273. PMC: 9877908. DOI: 10.1002/jmv.28273. View

10.

Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B . A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005; 11(8):875-9. PMC: 7095783. DOI: 10.1038/nm1267. View

11.

Rodriguez-Perez A, Labandeira C, Pedrosa M, Valenzuela R, Suarez-Quintanilla J, Cortes-Ayaso M . Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19. J Autoimmun. 2021; 122:102683. PMC: 8193025. DOI: 10.1016/j.jaut.2021.102683. View

12.

Son K, Jamil R, Chowdhury A, Mukherjee M, Venegas C, Miyasaki K . Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms. Eur Respir J. 2022; 61(1). PMC: 9515477. DOI: 10.1183/13993003.00970-2022. View

13.

Casciola-Rosen L, Thiemann D, Andrade F, Trejo-Zambrano M, Leonard E, Spangler J . IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. JCI Insight. 2022; 7(9). PMC: 9090251. DOI: 10.1172/jci.insight.158362. View

14.

Wang E, Mao T, Klein J, Dai Y, Huck J, Jaycox J . Diverse functional autoantibodies in patients with COVID-19. Nature. 2021; 595(7866):283-288. DOI: 10.1038/s41586-021-03631-y. View

15.

Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pohlmann S . TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol. 2013; 88(2):1293-307. PMC: 3911672. DOI: 10.1128/JVI.02202-13. View

16.

Meszaros B, Samano-Sanchez H, Alvarado-Valverde J, calyseva J, Martinez-Perez E, Alves R . Short linear motif candidates in the cell entry system used by SARS-CoV-2 and their potential therapeutic implications. Sci Signal. 2021; 14(665). PMC: 7928535. DOI: 10.1126/scisignal.abd0334. View

17.

Cantero-Navarro E, Fernandez-Fernandez B, Ramos A, Rayego-Mateos S, Rodrigues-Diez R, Sanchez-Nino M . Renin-angiotensin system and inflammation update. Mol Cell Endocrinol. 2021; 529:111254. DOI: 10.1016/j.mce.2021.111254. View

18.

Li W, Zhang C, Sui J, Kuhn J, Moore M, Luo S . Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 2005; 24(8):1634-43. PMC: 1142572. DOI: 10.1038/sj.emboj.7600640. View

19.

Feng A, Yang E, Moore A, Dhingra S, Chang S, Yin X . Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness. JCI Insight. 2023; 8(3). PMC: 9977421. DOI: 10.1172/jci.insight.163150. View

20.

Muri J, Cecchinato V, Cavalli A, Shanbhag A, Matkovic M, Biggiogero M . Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course. Nat Immunol. 2023; 24(4):604-611. PMC: 10063443. DOI: 10.1038/s41590-023-01445-w. View